[Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography]

Intravitreal injection of Conbercept combined with micropulse laser therapy enhances clinical efficacy in patients with diabetic macular edema

PURPOSE

To analyze the clinical efficacy of intravitreal injection of Conbercept (IVC) combined with micropulse laser (MPL) therapy in the treatment of diabetic macular edema (DME).

METHODS

In this retrospective study, we selected 64 DME patients who visited the First People's Hospital of Yunnan Province between February 2019 and February 2021 for analysis. Based on different intervention methods, 31 cases treated with IVC were included as a control group (the Con group) and 33 cases with IVC + MPL combination therapy were in a research group (the Res group). Data on curative effects, injection frequency, pre- and post-treatment best corrected visual acuity (BCVA) and central macular thickness (CMT), visual field gray value, 30° visual field average light threshold sensitivity, and mean visual field defect (VFD) were collected for inter-group comparisons. Further, Cox multivariate regression analysis was performed to identify factors affecting the curative efficacy of DME patients.

RESULTS

Compared with the Con group, the Res group had a higher total response rate and a lower injection frequency. In addition, higher BCVA and lower CMT were determined in the Res after 6 months of treatment. Moreover, Res group exhibited statistically lower visual field gray value and mean VFD, as well as higher 30° visual field average light threshold sensitivity than the Con at 1 month postoperatively. All the above differences were statistically significant. According to the Cox multivariate regression analysis, treatment modality was the influencing factor for the efficacy of DME patients.

CONCLUSIONS

IVC + MPL have better clinical efficacy than IVC alone for DME. The combined modality can improve patients' visual quality, inhibit DME, and reduce medication frequency.

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

Objective

To investigate the effect of intravitreal injection of triamcinolone acetonide and conbercept on the efficacy and safety of diabetic macular edema (DME) after cataract intraocular lens (IOL) surgery.

Methods

A total of 350 patients with cataract complicated with diabetic macular edema in our hospital from January 2017 to July 2021 were randomly divided into conbercept group and triamcinolone acetonide group. Patients in the conbercept group were given intravitreal injection of conbercept during IOL surgery, and patients in the triamcinolone acetonide group were given injection of triamcinolone acetonide during surgery.

Results

Three months after treatment, the best-corrected visual acuity of the two groups was significantly higher than before, the corrected visual acuity of the conbercept group was more significant than the triamcinolone acetonide group, and the intraocular pressure of the triamcinolone acetonide group was higher than the conbercept group. The foveal thickness and macular volume were significantly reduced in both groups, and was reduced more in the conbercept group than in the triamcinolone acetonide group. The contents of VEGF, SDF-1, and IL-6 in both groups were significantly decreased, and the decrease was more significant in the conbercept group than in the triamcinolone acetonide group. The patients with elevated intraocular pressure, headache and vomiting, orbital swelling pain, eye swelling pain, and eye pain in the triamcinolone acetonide group were significantly higher than those in the conbercept group (P < 0.05).

Conclusions

Conbercept and triamcinolone acetonide has a good therapeutic effect on DME in pseudophakic eyes after cataract IOL surgery, which can reduce the degree of macular edema and improve the visual function. However, the therapeutic effect of injection therapy with conbercept is safe, the prognosis is better, and the complication rate is low.